VIVAC forskargrupp: Vacciner och immunterapier mot virus och cancer – Matti Sällberg

Publikationer

Utvalda publikationer

Article: CELL HOST & MICROBE. 2023;31(6):928-936.e4
Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox
Adamo S; Gao Y; Sekine T; Mily A; Wu J; Storgard E; Westergren V; Filen F; Sandberg JK; Sallberg M; Bergman P; Llewellyn-Lacey S; Ljunggren H-G; Price DA; Ekstrom A-M; Sette A; Grifoni A; Buggert M
Journal article: VACCINE INSIGHTS. 2023;02(05):167-173
OPENCORONA: lessons learned from a pandemic vaccine consortium
Sällberg M; Gidlund E-K
Article: GUT. 2023;72(6):1186-1195
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
Burm R; Maravelia P; Ahlen G; Ciesek S; Perez NC; Pasetto A; Urban S; Van Houtte F; Verhoye L; Wedemeyer H; Johansson M; Frelin L; Sallberg M; Meuleman P
Preprint: BIORXIV. 2023
Phosphatidylinositol 4-kinase III alpha governs cytoskeletal organization for invasiveness of liver cancer cells
Tran CS; Kersten J; Breinig M; Yan J; Poth T; Colasanti O; Riedl T; Faure-Dupuy S; Diehl S; Verhoye L; Li T-F; Lingemann M; Schult P; Ahlén G; Frelin L; Kühnel F; Breuhahn K; Vondran FWR; Meuleman P; Heikenwälder M; Schirmacher P; Sällberg M; Bartenschlager R; Laketa V; Tschaharganeh DF; Lohmann V
Article: MOLECULAR THERAPY. 2023;31(2):387-397
Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model
Hawman DW; Meade-White K; Leventhal S; Appelberg S; Ahlen G; Nikouyan N; Clancy C; Smith B; Hanley P; Lovaglio J; Mirazimi A; Sallberg M; Feldmann H
Review: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2022;16:100099
ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing.
Silva DN; Chrobok M; Ahlén G; Blomberg P; Sällberg M; Pasetto A
Article: EMBO MOLECULAR MEDICINE. 2022;14(10):e15821
A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells
Appelberg S; Ahlen G; Yan J; Nikouyan N; Weber S; Larsson O; Hoglund U; Aleman S; Weber F; Perlhamre E; Apro J; Gidlund E-K; Tuvesson O; Salati S; Cadossi M; Tegel H; Hober S; Frelin L; Mirazimi A; Sallberg M
Article: JOURNAL OF VIROLOGY. 2022;96(3):e0156821-e01521
Nucleoside-Modified mRNA Vaccines Protect IFNAR^-/- Mice against Crimean-Congo Hemorrhagic Fever Virus Infection
Appelberg S; John L; Pardi N; Vegvari A; Bereczky S; Ahlen G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sallberg M; Neogi U; Weissman D; Mirazimi A
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:896242
Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products
Silva DN; Chrobok M; Rovesti G; Healy K; Wagner AK; Maravelia P; Gatto F; Mazza M; Mazzotti L; Lohmann V; Chen MS; Sallberg M; Buggert M; Pasetto A
Preprint: BIORXIV. 2021
Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection
Sandberg JT; Varnaitė R; Christ W; Chen P; Muvva J; Maleki K; García M; Dzidic M; Folkesson E; Skagerberg M; Ahlén G; Frelin L; Sällberg M; The Karolinska COVID-19 Study Group; Eriksson L; Rooyackers O; Sönnerborg A; Buggert M; Björkström N; Aleman S; Strålin K; Klingström J; Ljunggren H-G; Blom K; Gredmark-Russ S
Article: NATURE MICROBIOLOGY. 2021;6(2):187-195
A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model
Hawman DW; Ahlen G; Appelberg KS; Meade-White K; Hanley PW; Scott D; Monteil V; Devignot S; Okumura A; Weber F; Feldmann H; Sallberg M; Mirazimi A
Article: JOURNAL OF INFECTIOUS DISEASES. 2021;223(1):128-138
Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections
Maravelia P; Frelin L; Ni Y; Perez NC; Ahlen G; Jagya N; Verch G; Verhoye L; Pater L; Johansson M; Pasetto A; Meuleman P; Urban S; Sallberg M
Article: MOLECULAR & CELLULAR PROTEOMICS. 2021;20:100159
Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication
Krishnan S; Nordqvist H; Ambikan AT; Gupta S; Sperk M; Svensson-Akusjarvi S; Mikaeloff F; Benfeitas R; Saccon E; Ponnan SM; Rodriguez JE; Nikouyan N; Odeh A; Ahlen G; Asghar M; Sallberg M; Vesterbacka J; Nowak P; Vegvari A; Sonnerborg A; Treutiger CJ; Neogi U
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(7):e1306
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation
Sandberg JT; Varnaite R; Christ W; Chen P; Muvva JR; Maleki KT; Garcia M; Dzidic M; Folkesson E; Skagerberg M; Ahlen G; Frelin L; Sallberg M; Eriksson LI; Rooyackers O; Sonnerborg A; Buggert M; Bjorkstrom NK; Aleman S; Stralin K; Klingstrom J; Ljunggren H-G; Blom K; Gredmark-Russ S
Article: GUT. 2020;69(12):2203-2213
Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus
Lutckii A; Strunz B; Zhirkov A; Filipovich O; Rukoiatkina E; Gusev D; Lobzin Y; Fischler B; Aleman S; Sallberg M; Bjorkstrom NK
Article: JOURNAL OF IMMUNOLOGY. 2020;205(9):2437-2446
Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
Varnaite R; Garcia M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren H-G; Ahlen G; Frelin L; Sallberg M; Blom K; Klingstrom J; Gredmark-Russ S
Article: BMJ OPEN. 2020;10(9):e035996
Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study
Busch K; Hansson F; Holton M; Lagging M; Westin J; Kovamees J; Sallberg M; Soderholm J
Letter: JOURNAL OF VIROLOGY. 2020;94(18):e01279-e01220
The SARS-CoV-2 N Protein Is a Good Component in a Vaccine
Ahlen G; Frelin L; Nikouyan N; Weber F; Hoglund U; Larsson O; Westman M; Tuvesson O; Gidlund E-K; Cadossi M; Appelberg S; Mirazimi A; Sallberg M
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2020;16(2):251-268
Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance
Whitacre DC; Peters CJ; Sureau C; Nio K; Li F; Su L; Jones JE; Isogawa M; Sallberg M; Frelin L; Peterson DL; Milich DR
Review: FRONTIERS IN IMMUNOLOGY. 2020;11:552
Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation
Sallberg M; Pasetto A
Article: GUT. 2018;67(8):1525-1535
Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model
Levander S; Holmstrom F; Frelin L; Ahlen G; Rupp D; Long G; Bartenschlager R; Sallberg M
Visa fler

Finansiering

Forskningsbidrag

Doctoral Program in preclinical and clinical Advanced Therapies (DPAT).

Swedish Research Council

Genetic Vaccines and Immune-Based Therapies to Prevent Cancer Caused by Chronic Hepatitis B Virus and Hepatitis D Virus Infections: New Therapies and Models

Swedish Cancer Society

Genetic Vaccines and Immune-Based Therapies to Prevent Cancer Caused by Chronic Hepatitis B Virus and Hepatitis D Virus Infections: New Therapies and Models

Swedish Cancer Society

Vaccine and immunotherapies to prevent liver cancer caused by hepatitis B and D virus

Swedish Cancer Society

VIVAC forskargrupp: Vacciner och immunterapier mot virus och cancer – Matti Sällberg

Publikationer

Utvalda publikationer

Finansiering

Forskningsbidrag

Medarbetare och kontakt

Gruppledare

Alla medarbetare i gruppen